Exact Sciences has already set plans in place to try to benefit from new guidelines from the American Cancer Society, which is lowering the recommended age at which patients should first get screened for colorectal cancer from 50 to 45.
But fully realizing that objective, however, is still going to take plenty of time and money, according to industry analysts.
The ACS’s decision Wednesday sent shares in Madison, WI-based Exact (NASDAQ: EXAS) up by more than 11 percent that day, to $58.58 a share. The stock traded at $59.54 when the closing bell rang on Thursday.
Exact sells a… Read more »
UNDERWRITERS AND PARTNERS